Alemtuzumab, Rituximab ( DrugBank: Rituximab, Alemtuzumab )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 63 | Idiopathic thrombocytopenic purpura | 1 |
63. Idiopathic thrombocytopenic purpura
Clinical trials : 391 / Drugs : 235 - (DrugBank : 50) / Drug target genes : 49 - Drug target pathways : 139
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00749112 (ClinicalTrials.gov) | August 2008 | 8/9/2008 | Alemtuzumab and Rituximab in the Treatment of Refractory Autoimmune Cytopenias | Low Doses of Alemtuzumab and Rituximab in the Treatment of Refractory Autoimmune Cytopenias | Idiopathic Thrombocytopenic Purpura;Anemia, Hemolytic, Autoimmune | Drug: Alemtuzumab, Rituximab | Hospital Universitario Dr. Jose E. Gonzalez | NULL | Completed | 16 Years | N/A | Both | 19 | Phase 2/Phase 3 | Mexico |